The FDA loves horse medicine if it’s really expensive, still under patent, and toxic (Fauci, Baric, Denison, DTRA & Gilead Sciences)

The FDA loves horse medicine if it’s really expensive, still under patent, and toxic

Related:

Study shows effectiveness of pill form of remdesivir to treat COVID-19 in mice (Ralph Baric & Gilead Sciences)**

Molnupiravir & Ivermectin’s Equine Connections

An emerging antiviral takes aim at COVID-19

[Molnupiravir] EIDD-2801’s story starts years before the coronavirus crisis. In 2014, Painter and his colleagues at Emory University began a project funded by the Defense Threat Reduction Agency to find an antiviral compound that could fight Venezuelan equine encephalitis virus (VEEV). During the Cold War, both the US and the Soviet Union studied VEEV as a potential biological weapon. Typically transmitted through mosquito bites, VEEV causes high fevers, headaches, and sometimes encephalitis, swelling of the brain that can be deadly.

In late 2019, Painter got a contract from the National Institute of Allergy and Infectious Diseases* to move EIDD-2801 into Phase I clinical trials for influenza. The plan was to file an investigational new drug application and find a partner to help with the clinical work.

Just as the team was contemplating its next move, word of a virus spreading in Wuhan, China, was starting to make news. One of Painter’s collaborators, UNC coronavirus expert Ralph Baric**, immediately alerted him that the new pathogen was probably a coronavirus—one that EIDD-2801 could potentially combat.

Denison*** says the research team knew a coronavirus outbreak was inevitable. “Every single one of our grants, every single one of our papers predicted that this event was going to happen that’s occurring right now,” he says. “The whole goal of our drug development was to plan for this.”

*Anthony Fauci, director of NIAID.

**Ralph Baric, patents.

***Mark Denison (Denison Lab/Vanderbilt University Medical Center & Gilead Sciences)

J&J pauses production of its Covid-19 vaccine despite persistent need 💰

J&J pauses production of its Covid-19 vaccine despite persistent need

The facility, in the Dutch city of Leiden, has instead been making an experimental but potentially more profitable vaccine to protect against an unrelated virus.

But poorer countries remain reliant on Johnson & Johnson’s vaccine, which does not require ultracold refrigeration. It has been shown to provide strong and long-lasting protection against severe disease across variants, including omicron, when given as a two-shot regimen. As a single shot, the vaccine is less expensive and relatively easy to give to hard-to-reach populations.

Unlike companies such as Pfizer and Moderna, which have reaped billions of dollars in profits, Johnson & Johnson did not find the COVID vaccine to be a big moneymaker.

….

Since production of the COVID vaccine was halted late last year, the Netherlands plant has been manufacturing an experimental vaccine against respiratory syncytial virus, or RSV, that will be used for a clinical trial in older adults in wealthy countries, a person familiar with the matter said. Even if it proves effective, the vaccine is not expected to become available for several years.

WHO-led programme aims to buy antiviral COVID-19 pills for $10 -document

WHO-led programme aims to buy antiviral COVID-19 pills for $10 -document

Merck & Co’s experimental pill molnupiravir is likely to be one of the drugs, and other drugs to treat mild patients are being developed.

Although it does not explicitly cite molnupiravir, the ACT-A document expects to pay $10 dollar per course for “novel oral antivirals for mild/moderate patients”.

Another 4.3 million courses of repurposed COVID-19 pills to treat critical patients are also expected to be purchased at a price of $28 per course, the document says, without naming any specific drug.

Nebraska AG Says Doctors Can Legally Prescribe Ivermectin, HCQ for COVID, Calls Out FDA, CDC, Fauci, Media for ‘Fueling Confusion and Misinformation’

By Megan Redshaw | The Defender | October 18, 2021

Few subjects have been more controversial than ivermectin and hydroxychloroquine — two long-established, inexpensive medications widely and successfully used in many parts of the world for the prevention and treatment of COVID.

Nebraska AG Says Doctors Can Legally Prescribe Ivermectin, HCQ for COVID, Calls Out FDA, CDC, Fauci, Media for ‘Fueling Confusion and Misinformation’

A Sad and Shameful Day for Australian Medicine

September 10, 2021, was a black day, the day a group of faceless bureaucrats known as the “Advisory Committee for Medicines Scheduling”, through its effector arm, the Therapeutic Goods Administration (TGA), compromised medical practise and the health of their fellow Australians. The TGA used its regulatory muscle to prevent doctors at the COVID-19 pandemic’s coalface from prescribing ivermectin (IVM), the one therapy available that is safe, cheap and which reduces mortality in the order of 60 per cent. This poorly conceived action threatens the high standards of medical practise we have achieved in Australia, and the credibility of the administrative structure within which medicine operates.

A Sad and Shameful Day for Australian Medicine

A Legacy of Corruption in the FDA and Big Pharma

By Liam Cosgrove | Mises Wire | September 11, 2021

Our healthcare system is broken, a fact nobody would have disputed in precovid days. Regulatory capture is a reality, and the pharmaceutical industry is fraught with examples. Yet we trusted private-public partnerships to find an optimal solution to a global pandemic, assuming a crisis would bring out the best in historically corrupt institutions.

A Legacy of Corruption in the FDA and Big Pharma

Trust the $cience! 🙄